A Six Week Topical Cream Study for Subjects With Ichthyosis Vulgaris

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-04-25

Study Completion Date

2019-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to determine and compare the safety and efficacy of topical 146-9251 cream and vehicle cream applied twice daily for 6 weeks in subjects with moderate to severe ichthyosis vulgaris (IV).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis

NCT01413763

Actinic Keratosis

UNKNOWN PHASE4

Phase III Study of Monolaurin Cream Therapy for Patients With Congenital Ichthyosis

NCT00004690

Ichthyosis

COMPLETED PHASE3

A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis

NCT02667275

Seborrheic Keratosis

COMPLETED PHASE3

Cryosurgery and Cream Combination for Actinic Keratosis

NCT03037541

Actinic Keratosis

COMPLETED PHASE3

A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo

NCT03468855

Vitiligo

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ichthyosis Vulgaris

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Placebo controlled

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

146-9251 cream

Topical cream to be applied two times daily to specified treatment areas for 6 weeks.

Group Type ACTIVE_COMPARATOR

146-9251 cream

Intervention Type DRUG

146-9251 cream contains an active drug and is applied topically.

Vehicle cream

Topical cream to be applied two times daily to specified treatment areas for 6 weeks.

Group Type PLACEBO_COMPARATOR

Vehicle cream

Intervention Type DRUG

Vehicle cream does not contain an active drug and is applied topically.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

146-9251 cream

146-9251 cream contains an active drug and is applied topically.

Intervention Type DRUG

Vehicle cream

Vehicle cream does not contain an active drug and is applied topically.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject is a male or female and is at least 12 years old at the time of enrollment.
2. Subject has provided written informed consent/assent. A subject under 18 years of age must provide written informed assent and be accompanied by the parent or legal guardian at the time of assent/consent signing. The parent or legal guardian must provide informed consent for the subject. If a subject becomes 18 years of age during the study, the subject must provide written informed consent at that time to continue study participation.
3. Subject and parent/guardian (if applicable) are willing and able to apply the test article(s) as directed, comply with study instructions, and commit to all follow-up visits for the duration of the study.
4. Subject has a clinical diagnosis of ichthyosis vulgaris involving a minimum of 5% body surface area (BSA). If the subject has IV involving over 40% BSA, the investigator must be able to identify a Treatment Area comprising distinct anatomic units that contains about 40% (excluding the scalp and mucosal areas) as detailed in Section 6.2.
5. Subject has an Investigator's Global Assessment (IGA) score of at least three (3 = moderate) at the Baseline Visit.
6. Subject is in good general health and free of any disease state or physical condition that might impair evaluation of IV or which, in the investigator's opinion, exposes the subject to an unacceptable risk by study participation.
7. Females must be post-menopausal, surgically sterile, or use an effective method of birth control. , Women of childbearing potential (WOCBP) must have with a negative urine pregnancy test (UPT) at the Baseline Visit.

Exclusion Criteria

* 1\. Subject is pregnant, lactating, or is planning to become pregnant during the study.

2\. Subject is currently enrolled in an investigational drug or device study. 3. Subject has used an investigational drug or investigational device treatment within 30 days prior to first application of the test article.

4\. Subject has used any topical therapy, including topical corticosteroids or retinoids, in the Treatment Area within 2 weeks prior to the initiation of treatment. Note: a bland emollient may be used in the Treatment Area up to 3 days prior to the initiation of treatment.

5\. Subject has used systemic corticosteroids within 4 weeks or retinoids within 24 weeks prior to the initiation of treatment.

6\. Subject has stable use of vitamin or herbal supplements for less than 2 weeks prior to the initiation of treatment.

7\. Subject has a history of sensitivity to any of the ingredients in the test articles.

8\. Subject is known to be noncompliant or is unlikely to comply with the requirements of the study protocol (e.g., due to alcoholism, drug dependency, mental incapacity) in the opinion of the investigator.

9\. Subject has a physical condition or other dermatologic disorders (e.g., atopic, seborrheic or contact dermatitis, psoriasis, tinea infections, etc.) which, in the investigator's opinion, might impair evaluation of IV, or which exposes the subject to unacceptable risk by study participation.

Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No